What UPMA is doing
- Organizing Global Diabetes Walk on 14th November at 7 AM in front of Lekhraj Market–I, Indiranagar.
- Organizing an awareness talk of Dr. L.K. Shankhdhar on Healthy Life Style.
- Organizing painting competition and awareness talk at Bhartiya Vidya Bhawan, Gomtinagar, Lucknow.
- With Canara Bank, organinzing Awareness Talk of Dr. L.K. Shankhdhar, followed by Q&A session
- L.K. Diabetes Centre is the only private exclusive Diabetes Care Centre in North India.
- It undertakes several initiatives from 14th November:
- Launches Pre Diabetes Detection Unit: anybody can get himself checked for his glycemic status. Pre Diabetes is a Wake Up Call for anybody and it is mostly preventable.
- Launches Diabetes Education Unit under Dr. Smita Shankhdhar. All patients shall be rendered individual education as per their need. Dr. Smita Shankhdhar is the only Medico Educationist to perform this duty in India.
- Joining hands with Indira Diagnostic Centre to set up a Foot Check up Unit under Dr. Kshitij Shankhdhar.
- Rosiglitazone, available in India as Windia, Rezult, Enselin, Rosicon has been dropped from the list of ant diabetic drugs by American Diabetes Associations, recently. The drug has been found to increase risk of Heart attack, Heart failure, fractures and macular oedema, resulting into blindness.
- A new drug, Rimonabent, introduced in India approximately two year before, has been withdrawn from European market on instructions of Drug Controller. Its international brand is Accomplia by Aventis. The drug has been found to increase the risk of Depression and Suicide. Unfortutunately the drug is available even as OTC (one the counter) product in India.
- Latest guideline regarding management of Diabetes by American Diabetes Association as well as European Association for Study of Diabetes have suggested Metformin as first line drug for patients failing to achieve control on Diet and exercise. The second line includes Basal Insulin therapy, Sulfonyl Urea, Pioglitazone and Incretin Mimetics. The third line suggests to include Basal Insulin therapy followed by Intensive Insulin therapy as step care measures.
- Alfa Glucosidase Inhibitors, namely Acarbose (Glucobay), Miglitol (Migtor, Mignar) and Voglibose (Volibo, Volix, Voglitor), Glinides such as Repaglinide (Europa), Nateglinide (Glinate) and DPP4 Inhibitors, namely Sitagliptin (Januvia) and Vildgliptin (Galvus) have been dropped from the new list of anti diabetic drugs.
Dr. L. K. Shankhdhar
M.D. (Med.), DMRE, PGDND, MAMS, FICN